Tiger / Tiger 2 / Tiger OCT ↗
Current CoreLink-origin fixation family including posterior, MIS and OCT offerings. [224]
FDA-clearedPrivately held spine-device manufacturer with a distributor-led commercial model and acquired CoreLink and ChoiceSpine portfolios.
Zavation Medical Products is a privately held manufacturer of spinal implants, interventional spine products and biologics, headquartered in Flowood, Mississippi, with a St. Louis-area facility. Current company announcements give 2012 as its founding year. Its portfolio spans cervical and lumbar interbodies, posterior fixation, SI joint fusion, vertebral augmentation and bone graft products.
Zavation is backed by Gemspring Capital and emphasizes distributor support, product training and in-house manufacturing. It acquired Pan Medical U.S. in 2018, CoreLink in 2023 and ChoiceSpine in February 2026. ChoiceSpine continues to operate under its own brand. Current-family regulatory records therefore include original Zavation, CoreLink, ChoiceSpine and Expanding Orthopedics applicant names, with pre-acquisition decisions identified.
Recent releases include Varisync ALIF and NanoPrime/Labyrinth cervical offerings. The company reported a Varisync first case at Hartford Hospital; that is a company-attributed use, not proof of system-wide adoption. Materials testing and surgeon feedback should not be treated as comparative clinical outcomes. This profile records two terminated recall events associated with current families and does not repeat historical zero-recall marketing as a current group-wide claim. Revenue, deal values and confirmed payer coverage were not established in this review.
The expanded group combines original Zavation devices with CoreLink, ChoiceSpine and acquired FLXfit families. FDA applicant names remain as filed; an older decision can belong to a current family without every historical model still being marketed. Preclinical performance, product launch and FDA marketing authorization are separate facts. The FDA decision/recall searches are completed for the named company and acquired applicants. Some supplier-origin biologic/cement and legacy records are not linked to a selected current commercial family. [221][227][218][213][114][48][225][228][2]
The matched FDA history contains 2 distinct recall events: 0 open, 2 terminated. 1 were initiated during the five years beginning October 20, 2021; older open events are also retained. Z-0954-2023 (2022-10-20; terminated): Specific lots of FLXfit implants have internal components that may have been manufactured using stainless steel rather than the specified titanium alloy. Z-1700-2021 (2021-03-25; terminated): Products distributed as sterile may not have been adequately sterilized [202][131][132][133][134][135][136][137][138][139][140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155][156][157][158][159][160][161][162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180][181][182][183][184][185][186][187][188][189][190][191][192][193][194][195][196][197][198][199][200][201]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Current CoreLink-origin fixation family including posterior, MIS and OCT offerings. [224]
FDA-clearedCurrent Zavation posterior fixation family and associated connection hardware. [221]
FDA-clearedCurrent families include IBF/Whitney, Ti3Z, Labyrinth/NanoPrime, eZspand, Varisync, F3D, CL5 and M3. Shared-family decisions counted once. [221]
FDA-clearedCurrent cervical plating families listed in the IFU catalog. [221]
FDA-clearedCurrent compatible instruments documented in IFUs; platform compatibility is not itself a commercial partnership. [226]
FDA-clearedCurrent vertebral augmentation family. One terminated recall event spans current-family and unresolved legacy product rows. [225]
FDA-clearedCurrent cervical family; exact stand-alone criteria depend on labeling. [221]
FDA-clearedCurrent static and expandable plate family. [221]
FDA-clearedCurrent CoreLink-origin anterior/lateral plate families. [221]
FDA-clearedCurrent cervical and thoracolumbar corpectomy families. [221]
FDA-clearedCurrent SI family includes acquired CoreLink-origin systems and Zavation SI Screw. [223]
FDA-clearedCurrent synthetic and collagen graft offerings plus allografts. Tissue supplier and pathway mapping is incomplete; do not treat all products as cleared or exempt. [221]
Marketed · regulatory scope variesExpanding Orthopedics-origin technology acquired by CoreLink in 2018, then into Zavation's group in 2023. FLXfit15 is currently listed. [214]
FDA-clearedCurrent ChoiceSpine family retained under the ChoiceSpine brand. [209]
FDA-clearedCurrent ChoiceSpine fixation families. [211]
FDA-clearedCurrent Blackhawk Ti, Tomcat, Ascendant, Stealth and TigerShark C offerings; historical family decisions do not establish continued sale of every prior model. [209]
FDA-clearedCurrent Boomerang, Falcon and Ambassador families. [209]
FDA-clearedCurrent TigerShark, Harrier, Octane, Shark, Harpoon and VEO families. [210]
FDA-clearedRecent material-platform and product releases are treated as commercial activity where documented. A separately verified, complete development pipeline was not established; unlinked historical clearances do not automatically become active development programs. [229][228]
ChoiceSpine retained its brand and operations under common ownership. Derek Kuyper was appointed CEO of the combined organization; transaction terms were undisclosed. [227]
Company reported its combined implant-material release. Preclinical surface and bone-growth findings do not establish human comparative superiority. [229]
Company announcement reported first clinical use in August 2024 by Hanbing Zhou at Hartford Hospital. A reported first case is not an audited hospital-wide adoption count. [228]
Zavation announced the CoreLink acquisition from The Stephens Group, adding spinal implant and manufacturing capabilities. Earlier CoreLink and Expanding Orthopedics records retain original attribution. [218]
FDA event 91109 involved specific lots of FLXfit15 with a potential incorrect internal material. The event was terminated August 20, 2024; it is not an open recall. [216]
Zavation and LongueVue announced the transaction with Pan Medical U.S. management, expanding vertebral augmentation. Do not assume ownership of every Pan Medical Ltd. FDA record. [217]
Current company announcements identify 2012 as founding. Earlier FDA applicant records exist; legal-formation versus commercial-launch dates require confirmation. [227]
Accessed 10/20/2026